Exchange: NASDAQ Sector: Healthcare Industry: Diagnostics & Research
-4.92% $2.32
America/New_York / 19 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 12.97 mill |
EPS: | -0.150 |
P/E: | -15.47 |
Earnings Date: | Aug 29, 2024 |
SharesOutstanding: | 5.59 mill |
Avg Daily Volume: | 0.0301 mill |
RATING 2024-04-19 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Strong Sell | |
DE: | Neutral | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | ||||
Gr.Profit | n/a | n/a | ||||
Ebit | n/a | n/a | ||||
Asset | n/a | n/a | n/a | n/a | ||
Debt | n/a | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -15.47 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.83x |
Company: PE -15.47 | industry: PE 18.71 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 2.12 - 2.52 ( +/- 8.62%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2004-08-24 | Patou Gary | Sell | 2 500 | Stock Options |
2004-08-25 | Patou Gary | Sell | 5 500 | Stock Options |
2004-07-01 | Hennessey Robert J | Sell | 1 500 | Stock Options |
2004-06-29 | Kirby Pamela J | Buy | 9 047 | Stock Options(right to buy) |
2004-06-29 | Kirby Pamela J | Buy | 25 000 | Stock Options(right to buy) |
INSIDER POWER |
---|
0.00 |
Last 92 transactions |
Buy: 380 693 | Sell: 1 344 573 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $2.32 (-4.92% ) |
Volume | 0.0643 mill |
Avg. Vol. | 0.0301 mill |
% of Avg. Vol | 213.96 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include cardiovascular, type 2 diabetes, prostate cancer, and melanoma. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.